

# Oncology Breast Cancer (drugs J-T)



(Kisqali®, Lynparza®, Nerlynx™, Talzenna™, Tykerb®)

Patient Information	Prescriber + Shipping Information
Patient name: _____ DOB: _____ Sex: <input type="checkbox"/> Female <input type="checkbox"/> Male SSN: _____ Language: _____ Wt: _____ <input type="checkbox"/> kg <input type="checkbox"/> lbs Ht: _____ <input type="checkbox"/> cm <input type="checkbox"/> in Address: _____ Apt/Suite: _____ City: _____ State: _____ Zip: _____ Phone: _____ Alternate: _____ Caregiver name: _____ Relation: _____ Local pharmacy: _____ Phone: _____ Insurance plan: _____ Plan ID: _____	Prescriber name: _____ NPI: _____ Address: _____ Apt/Suite: _____ City: _____ State: _____ Zip: _____ Contact: _____ Phone: _____ Alternate: _____ Fax: _____ Email: _____ If shipping to prescriber: <input type="checkbox"/> First Fill <input type="checkbox"/> Always <input type="checkbox"/> Never

**Please fax a copy of front and back of the insurance card(s).**

## Clinical Information (Please fax all pertinent clinical and lab information)

**Diagnosis (C00-D49):** \_\_\_\_\_ **Diagnosis date:** \_\_\_\_\_

Mutations:  HER2  \_\_\_\_\_ **ER:**  Positive  Negative **PR:**  Positive  Negative

Prior Therapy <input type="checkbox"/> Yes <input type="checkbox"/> No	Reason for Discontinuation of Therapy	Approximate Start Date	Approximate End Date
_____	_____	_____	_____
_____	_____	_____	_____

Comorbidities: \_\_\_\_\_

Concomitant Medications: \_\_\_\_\_

Allergies:  NKDA  Other: \_\_\_\_\_

## Prescription

Prescription	Quantity	Refill
§Afinitor® and Ibrance® are listed alphabetically on respective enrollment forms.§		
<b>Kisqali® (ribociclib)</b>	Take 600 mg by mouth once daily on days 1-21 of a 28-day cycle Patient will be obtaining an aromatase inhibitor at: Diplomat (fill prescription below) <input type="checkbox"/> Other pharmacy <input type="checkbox"/> Not receiving (Reason: _____)	63 x 200 mg tablets
<b>Kisqali® (ribociclib) Femara® Co-pack (letrozole)</b>	Take 600 mg of Kisqali® by mouth once daily on days 1-21 with 2.5 mg of Femara® by mouth once daily on days 1-28 of a 28-day cycle.	63 x 200 mg tablets of Kisqali® 28 x 2.5 mg tablets of Femara®
<b>Lynparza® (olaparib)</b>	Take 300 mg by mouth twice daily	120 x 150 mg tablets
<b>Nerlynx™ (neratinib)</b>	Take 240 mg by mouth once daily with food	180 x 40 mg tablets
<b>Loperamide</b>	Take 4 mg by mouth three times daily for days 1-14; then take 4 mg by mouth twice daily for days 15-30	148 x 2 mg capsules
	Take 4 mg by mouth twice daily for days 31-56	104 x 2 mg capsules
	Take 4 mg by mouth as needed (not to exceed 16 mg per day)	_____ x 2 mg capsules
<b>Talzenna™ (talazoparib)</b>	Take 1 mg by mouth once daily	30 x 1 mg capsules
<b>Tykerb® (lapatinib)</b>	Take 1,250 mg by mouth once daily at least one hour before or after a meal	105 x 250 mg tablets
	Take 1,500 mg by mouth once daily at least one hour before or after a meal	180 x 250 mg tablets
<b>Xeloda® (capecitabine)</b>	Take _____ mg (_____ mg/m <sup>2</sup> /dose x _____ m <sup>2</sup> ) by mouth twice daily (every 12 hours) within 30 minutes after a meal on days 1-14 of a 21-day cycle	_____ x 150 mg tablets _____ x 500 mg tablets
<b>Femara® (letrozole)</b>	Take 2.5 mg by mouth once daily	30 x 2.5 mg tablets
_____ <input type="checkbox"/> _____	_____	_____

§Verzenio™ and Xeloda® are listed alphabetically on respective enrollment forms.§

## Endocrine Therapy Options

Medication	Directions	Quantity	Refill
Evista® (raloxifene) Fareston® (toremifene) Nolvadex® (tamoxifen)			
Arimidex® (anastrozole) Aromasin® (exemestane) <input type="checkbox"/> Femara® (letrozole)			
Faslodex® (fulvestrant)			

Per state-specific law, prescriptions will be dispensed as generic, if applicable, unless notated otherwise: \_\_\_\_\_

Stamp signature not allowed, physician signature required.

Prescriber's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

I authorize Diplomat Pharmacy, Inc. and its representatives to act as an agent to initiate and execute the insurance prior authorization process for this prescription and any future fills of the same prescription for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to Diplomat Pharmacy, Inc.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling 810.768.9178 or by emailing compliance@diplomat.is to obtain instructions as to the proper destruction of the transmitted material. Thank you. 11132018